Trulicity Takes Hit From Payer Mix, But Lilly Emerges From Q3 Ahead

COVID-19 Antibody Bamlanivimab Fails In Sicker Patients

 
• By Joseph Haas
US-Money-and-Pills_V2_1200x675
Lilly's revenue is growing despite the pandemic, but not without COVID-19-related headwinds

More from Earnings

More from Business